More than 80% of SLE patients experience some type of neurologic manifestation during their disease course. The challenge for rheumatologists and other clinicians lies in appropriately diagnosing any cognitive dysfunctions that accompany lupus and better understanding the causes and risk factors of those dysfunctions. “Cognitive Function in SLE” was the focus of a talk at the 2011 ACR/ARHP Annual Scientific Meeting in November.
Unique neuropsychiatric problems require a unique approach
A recent prospective, observational cohort study of potential clinical biomarkers for progression to interstitial lung disease (ILD) in patients with early systemic sclerosis (SSc) found that higher levels of CCL2 circulating in their plasma predicted both faster ILD progression and poorer survival rates than in those with lower levels.1 CCL2, also known as monocyte chemoattractant…
Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.